Athira Pharma, Inc (ATHA)

Etorro trading 970x250
Athira Pharma, Inc (ATHA) Logo

About Athira Pharma, Inc

Athira Pharma, Inc., a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer’s and Parkinson’s diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington. Address: 18706 North Creek Parkway, Bothell, WA, United States, 98011

Athira Pharma, Inc News and around…

Latest news about Athira Pharma, Inc (ATHA) common stock and company :

Noteworthy Wednesday Option Activity: ATHA, MRK, ORGO
12 Jan, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Athira Pharma Inc (ATHA), where a total of 1,410 contracts have traded so far, representing approximately 141,000 underlying shares. That amounts to about 46.3% of ATHA's average daily trading volume over the past month of 304,775 shares..

XPH's Underlying Holdings Imply 54% Gain Potential
10 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $69.00 per unit.

Athira Pharma Provides 2022 Pipeline Outlook
05 Jan, 2022 Yahoo! Finance

Topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 LIFT-AD Phase 3 Alzheimer’s disease study sample size increased to strengthen statistical power of co-key secondary endpoints and enhance the potential for a single pivotal clinical study Milestones achieved with initiation of SHAPE Phase 2 Parkinson’s disease dementia clinical trial and IND filing for ATH-1020 BOTHELL, Wash., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceu

Noteworthy Wednesday Option Activity: SQ, ATHA, IRBT
22 Dec, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Block Inc (SQ), where a total volume of 95,231 contracts has been traded thus far today, a contract volume which is representative of approximately 9.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 92.6% of SQ's average daily trading volume over the past month, of 10.3 million shares..

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
15 Dec, 2021 FinancialContent

Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:OGS) from Neutral to Buy. For the third ...

Is the Options Market Predicting a Spike in Athira Pharma (ATHA) Stock?
13 Dec, 2021 Yahoo! Finance

Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.

What Kind Of Shareholders Own Athira Pharma, Inc. (NASDAQ:ATHA)?
13 Dec, 2021 Yahoo! Finance

A look at the shareholders of Athira Pharma, Inc. ( NASDAQ:ATHA ) can tell us which group is most powerful. Generally...

Notable Monday Option Activity: SNOW, OKTA, ATHA
06 Dec, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Snowflake Inc (SNOW), where a total of 23,382 contracts have traded so far, representing approximately 2.3 million underlying shares. That amounts to about 59.1% of SNOW's average daily trading volume over the past month of 4.0 million shares..

Analysts Forecast 37% Gains Ahead For The Holdings of VTWO
03 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $121.12 per unit.

Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
10 Nov, 2021 Yahoo! Finance

– Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates and baseline data from ATH-1017’s ongoing Phase 2 and Phase 2/3 clinical trials at the 2021 CTAD conference – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neurona

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
10 Nov, 2021 Yahoo! Finance

– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira, presented an overview and updates from two ongoing late-st

Athira Pharma to Present at Upcoming Investor Conferences
08 Nov, 2021 Yahoo! Finance

-Stifel 2021 Virtual Healthcare Conference-- Jefferies 2021 London Healthcare Conference- BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences: Stifel’s 2021 Virtual Healthcare Conference Format: Fireside chatDate & Time:

July 2022 Options Now Available For Athira Pharma (ATHA)
02 Nov, 2021 FinancialContent

Investors in Athira Pharma Inc (ATHA) saw new options become available today, for the July 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 255 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300
29 Oct, 2021 Yahoo! Finance

Neurologist Dr. John Michael Olichney to discuss utility of P300 to assess cognitive function Webinar to be held Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET BOTHELL, Wash., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it will host an educational webinar to review event-related potential (ERP) P300 latency as a function

Former Athira CEO addresses controversy and departure in letter to employees
25 Oct, 2021 Yahoo! Finance

Leen Kawas, who resigned from her position as CEO and president of Athira, had been on temporary leave since June.

(ATHA) Alert: Did You Acquire Athira Before November 2020? Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel
23 Oct, 2021 Yahoo! Finance

SAN DIEGO, Oct. 23, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) against certain of its officers and directors. Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of Athira from September 18, 2020 and June 17, 2021 (the "Class Period"). The Athira Pharma class-action lawsuit alleges that, throughout the Class Period, d

Notable Friday Option Activity: GME, ROKU, ATHA
22 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in GameStop Corp (GME), where a total volume of 81,049 contracts has been traded thus far today, a contract volume which is representative of approximately 8.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 472.8% of GME's average daily trading volume over the past month, of 1.7 million shares..

35 Stocks Moving In Friday's Mid-Day Session
22 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with ...

Athira CEO Resigns After Data Manipulation Firestorm, But Alzheimer's Stock Pops
22 Oct, 2021 FinancialContent

Leen Kawas resigned from her post as Athira CEO after an investigation found she manipulated data in papers — and ATHA stock soared.

Athira Pharma Stock Climbs on Alzheimer's Test; CEO Resignation
22 Oct, 2021 Yahoo! Finance

Pharma company launches phase 2 trial of Alzheimer treatment as CEO steps down over altered images in her research papers and dissertation.

Why Shares of Athira Pharma Are Climbing Today
22 Oct, 2021 FinancialContent

The clinical trial for its Alzheimer's drug is one step closer to completion.

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
22 Oct, 2021 Yahoo! Finance

-Topline data targeted for 1H22- BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced today that it has completed enrollment in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease. ATH-1017 is a small molecule designed to enhance the activity of H

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
22 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating ...

Leen Kawas officially out at Athira after investigation finds doctored research
21 Oct, 2021 Yahoo! Finance

The move follows months of inquiry during which the former Athira CEO was placed on temporary leave.

Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer
21 Oct, 2021 Yahoo! Finance

Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas’s Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira. Dr

Notable Wednesday Option Activity: CCXI, X, ATHA
06 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ChemoCentryx, Inc. (CCXI), where a total of 14,773 contracts have traded so far, representing approximately 1.5 million underlying shares..

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases
05 Oct, 2021 FinancialContent

Image by Gerd Altmann from Pixabay How well we think, feel and act rests in the hands of trillions of tiny connectors in our ...

NASDAQ:ATHA Long Term Investor Notice: Investigation of Potential Wrongdoing at Athira Pharma, Inc.
01 Oct, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 10/01/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Athira Pharma, Inc.

Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
29 Sep, 2021 FinancialContent
Notable Wednesday Option Activity: OPRX, ATHA, MPC
22 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in OptimizeRx Corp (OPRX), where a total volume of 834 contracts has been traded thus far today, a contract volume which is representative of approximately 83,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.6% of OPRX's average daily trading volume over the past month, of 195,935 shares..

Athira Pharma, Inc (ATHA) is a NASDAQ Common Stock listed in , ,

970x250